Press Release Archive

12.08.2014

Anticoagulant Effect of Eliquis (apixaban) Reversed by Two Separate 4-Factor Prothrombin Complex Concentrates in Healthy Subjects

12.08.2014

iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for Discovery and Development of Cancer Immunosuppression Targets

12.08.2014

Spark Therapeutics Announces Gene Therapy Collaboration in Hemophilia B with Pfizer Inc.

12.08.2014

Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform

12.03.2014

Phase 3 Results Published in The New England Journal of Medicine Show Superiority of Pfizer’s XALKORI® (crizotinib) Compared to Platinum-Based Chemotherapy in Previously Untreated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

12.03.2014

WADA Signs a Global Collaboration Agreement with Pfizer Inc.

12.02.2014

Lpath Completes Enrollment in its Phase 2 Clinical Trial of iSONEP for Wet Age-Related Macular Degeneration

12.02.2014

New Survey Finds Majority of Women with Breast Cancer Who Work Want to Do So Even While Undergoing Treatment

12.01.2014

Pfizer Completes Acquisition of Baxter’s Marketed Vaccines

11.18.2014

Sanguine’s Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research

11.18.2014

TRUMENBA® (Meningococcal Group B Vaccine) is Now Available

11.17.2014

Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results From the First Part of the Phase 3 ANNEXA(TM)-A Studies of Investigational Andexanet Alfa With Eliquis (apixaban)